查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1535584

重症監護診斷市場 - 按產品、測試類型、最終用途 - 全球預測

Critical Care Diagnostics Market - By Product, Test Type, End-use - Global Forecast
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在領先公司之間合作夥伴關係數量不斷增加的推動下，2024 年至 2032 年間，全球重症監護診斷市場的複合年成長率將達到 5.5%。這些合作正在加強對重症監護環境至關重要的先進診斷技術的開發和推廣。例如，2024 年 6 月，Radiometer 和 Etiometry 建立了新的商業合作夥伴關係，旨在改善醫院環境中的臨床決策和工作流程。根據此次合作，Etiometry 的平台將與 Radiometer 的急診診斷解決方案整合，使重症監護臨床醫生能夠在單一螢幕上獲取血液氣體結果、基本臨床資料、其他生理參數和人工智慧驅動的患者風險分析。

這些工具對於準確、及時地診斷重症監護環境中的複雜狀況至關重要。合作夥伴關係也有助於分擔研發成本，提高效率並更快地將新產品推向市場。隨著醫療保健提供者越來越需要精確可靠的診斷解決方案來管理重症患者，這些策略聯盟對於滿足此需求和推動市場成長至關重要。因此，重症監護診斷市場正在迅速擴大，反映出合作努力在推動醫療保健技術方面的重要性。

整個重症監護診斷行業根據產品、測試類型、最終用途和地區進行分類。

根據產品，心臟代謝診斷試劑盒領域的重症監護診斷市場收入將在2024 年至2032 年實現值得稱讚的複合年成長率。重要，這些疾病在心臟病、糖尿病和代謝症候群等疾病中普遍存在。透過提供快速、準確的診斷訊息，心臟代謝套件使醫療保健提供者能夠做出明智的決策並根據患者的個別需求量身定做治療方案。心臟代謝疾病發生率的不斷上升以及對早期檢測和個人化護理的重視正在推動這些診斷工具的採用。因此，重症監護診斷市場不斷擴大，反映出對先進、精確診斷解決方案的需求。

在測試類型方面，血液學測試部分將在 2024 年至 2032 年期間出現顯著成長。在重症監護環境中，及時、準確的血液學結果對於有效的患者管理和治療決策至關重要。血液疾病的日益普及以及緊急情況和重症監護環境中快速診斷的需求導致了需求的不斷成長。因此，血液學檢測技術的進步正在推動市場成長並改善患者的治療結果。

歐洲重症監護診斷市場從 2024 年到 2032 年將呈現適度的複合年成長率。這包括即時監測系統、先進成像和快速診斷分析的整合。推動更好的患者護理，加上監管支援和醫療基礎設施投資，推動了該市場的成長。此外，歐洲人口老化和慢性病發病率上升進一步推動了對創新重症監護診斷解決方案的需求不斷成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 老年人口不斷增加
      • 慢性病和生活方式相關疾病的盛行率上升
      • 遠距醫療服務和遠距通訊的採用不斷增加
    • 產業陷阱與挑戰
      • 分子診斷工具成本高
      • 缺乏熟練的專業人員
  • 成長潛力分析
  • 監管環境
  • 技術景觀
    • 核心技術
    • 鄰近技術
  • 2023 年定價分析
    • 按地區
    • 按關鍵人物
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

  • 主要趨勢
  • 血糖診斷試劑盒
  • 心臟代謝診斷試劑盒
  • 傳染病檢測試劑盒
  • 血液學檢測試劑盒
  • 凝血診斷試劑盒
  • 癌症標記物檢測試劑盒
  • 其他產品

第 6 章：市場估計與預測：按測試類型，2021 - 2032 年

  • 主要趨勢
  • 流式細胞儀
  • 血液學檢查
  • 微生物學和感染性測試
  • 凝血試驗
  • 免疫蛋白
  • 常規和特殊化學
  • 其他測試類型

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 手術室
  • 重症監護室
  • 急診室
  • 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 9 章：公司簡介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies, Inc.
  • Hologic, Inc.
  • Johnson & Johnson
  • Koninklijke Philips N.V.
  • Medtronic plc
  • Nihon Kohden Corporation
  • Nova Biomedical
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
簡介目錄
Product Code: 9740

Global Critical Care Diagnostics Market will witness 5.5% CAGR between 2024 and 2032, driven by the rising number of partnerships between leading companies. These collaborations are enhancing the development and distribution of advanced diagnostic technologies crucial for critical care settings. For instance, in June 2024, Radiometer and Etiometry entered into a new commercial partnership aimed at improving clinical decision-making and workflows in hospital environments. Under this collaboration, Etiometry's platform will be integrated with Radiometer's acute care diagnostic solutions, enabling critical care clinicians to access blood gas results, essential clinical data, additional physiological parameters, and AI-driven patient risk analytics all on a single screen.

These tools are essential for the accurate and timely diagnosis of complex conditions in critical care environments. Partnerships also facilitate the sharing of research and development costs, improving efficiency and bringing new products to market faster. As healthcare providers increasingly demand precise and reliable diagnostic solutions to manage critically ill patients, these strategic alliances are pivotal in meeting that need and driving market growth. Consequently, the Critical Care Diagnostics market is expanding rapidly, reflecting the importance of collaborative efforts in advancing healthcare technology.

The overall Critical Care Diagnostics Industry is classified based on the product, test type, end-use, and region.

Based on product, the critical care diagnostics market revenue from the cardiometabolic diagnostic kits segment will register a commendable CAGR from 2024 to 2032. These kits are crucial for assessing and managing conditions such as heart disease, diabetes, and metabolic syndrome, which are prevalent in critical care settings. By providing rapid and accurate diagnostic information, cardiometabolic kits enable healthcare providers to make informed decisions and tailor treatments to individual patient needs. The growing incidence of cardiometabolic disorders and the emphasis on early detection and personalized care are driving the adoption of these diagnostic tools. As a result, the market for critical care diagnostics is expanding, reflecting the need for advanced and precise diagnostic solutions.

In terms of test type, the hematology test segment will register appreciable growth from 2024 to 2032. Hematology tests, including complete blood counts and coagulation profiles, provide essential information on blood disorders, infection, and overall health status. In critical care settings, timely and accurate hematology results are vital for effective patient management and treatment decisions. The growing prevalence of hematological conditions and the need for rapid diagnostics in emergency and intensive care environments contribute to the rising demand. Consequently, advancements in hematology testing technologies are fueling market growth and improving patient outcomes.

Europe critical care diagnostics market will exhibit a modest CAGR from 2024 to 2032. European healthcare systems are increasingly adopting advanced diagnostic technologies to enhance the accuracy and efficiency of critical care management. This includes the integration of real-time monitoring systems, advanced imaging, and rapid diagnostic assays. The push for better patient care, coupled with regulatory support and investment in healthcare infrastructure, drives the growth of this market. Additionally, Europe's aging population and rising incidence of chronic conditions further contribute to the increasing demand for innovative critical care diagnostic solutions.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing geriatric population
      • 3.2.1.2 Rise in the prevalence of chronic diseases and lifestyle-related disorders
      • 3.2.1.3 Rising adoption of telehealth services and remote communications
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of molecular diagnostics tools
      • 3.2.2.2 Lack of skilled professionals
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Pricing analysis, 2023
    • 3.6.1 By region
    • 3.6.2 By key player
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Glucose diagnostic kits
  • 5.3 Cardiometabolic diagnostic kits
  • 5.4 Infectious disease testing kits
  • 5.5 Hematology testing kits
  • 5.6 Coagulation diagnostic kits
  • 5.7 Cancer marker testing kits
  • 5.8 Other products

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Flow cytometry
  • 6.3 Hematology test
  • 6.4 Microbiology and infectious test
  • 6.5 Coagulation test
  • 6.6 Immunoprotein
  • 6.7 Routine and special chemistry
  • 6.8 Other test types

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Operation room
  • 7.3 Intensive care unit
  • 7.4 Emergency rooms
  • 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Becton, Dickinson and Company
  • 9.3 Bio-Rad Laboratories, Inc.
  • 9.4 Danaher Corporation
  • 9.5 F. Hoffmann-La Roche Ltd.
  • 9.6 GE HealthCare Technologies, Inc.
  • 9.7 Hologic, Inc.
  • 9.8 Johnson & Johnson
  • 9.9 Koninklijke Philips N.V.
  • 9.10 Medtronic plc
  • 9.11 Nihon Kohden Corporation
  • 9.12 Nova Biomedical
  • 9.13 Siemens Healthineers AG
  • 9.14 Sysmex Corporation
  • 9.15 Thermo Fisher Scientific Inc.